GHRP-2.

Both act as agonists at the ghrelin receptor GHS-R1a, so they compete for one binding site rather than adding a second mechanism. Ipamorelin is the more selective of the two, with less effect on cortisol and prolactin.

Hexarelin is another ghrelin receptor agonist in the same peptide class. Combining it with GHRP-2 loads one receptor twice and carries the class effects on cortisol and prolactin further.

Tesamorelin works at the growth hormone releasing hormone receptor while GHRP-2 works at the ghrelin receptor and lowers somatostatin tone. Engaging both arms of the axis gives a larger release than either does alone.

Arginine reduces somatostatin tone at the pituitary. Since ghrelin receptor agonists also work partly by easing that same brake, the two overlap on one of their mechanisms.

Glucose and the insulin it triggers raise somatostatin and suppress pituitary growth hormone release. A carbohydrate load close to dosing reduces the pulse the peptide is meant to create.

Ornithine is one of the basic amino acids that modestly stimulates growth hormone release, and it shares that route with arginine through reduced somatostatin tone. GHRP-2 acts at a different receptor, so the inputs are not the same input twice. No human study has tested the two together, and the amino acid signal on its own is small.

Lysine is usually paired with arginine in growth hormone secretagogue stacks because the two share the cationic amino acid transporters and are dosed together in older amino acid work. Alongside a receptor agonist such as GHRP-2, lysine contributes substrate rather than a second secretory signal. The pairing is a formulation convention with thin human backing.

Zinc is required across the enzymes and transcription factors that carry a growth hormone signal into hepatic IGF-1 output, and low zinc status is associated with lower circulating IGF-1, an association rather than a demonstrated cause. Raising a growth hormone pulse without the cofactors that translate it downstream gives less of a signal to work with. The link is nutritional status supporting a normal axis, not a combination trial.

Growth hormone and IGF-1 signalling only build tissue when amino acids are present to build it from, and whey isolate supplies leucine-rich substrate quickly. This is substrate availability rather than any effect on the secretory pulse itself. No study has paired the two.

A rise in circulating free fatty acids feeds back at the pituitary and blunts the growth hormone response to a secretagogue. A fat load taken close in time to GHRP-2 therefore works against the pulse the peptide is meant to produce. Worth flagging as timing, not as an incompatibility, and the size of the blunting has not been measured for this pairing.

Most endogenous growth hormone is released in early slow wave sleep, and melatonin shifts the timing of that window rather than the hormone itself. Anything that moves sleep onset moves where a secretagogue pulse lands relative to the natural one. This is a timing interaction inferred from physiology, with no combination data.